ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Setembro 2023 - 6:00PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the compensation committee of the Company’s
Board of Directors (the “Compensation Committee”) approved,
effective as of September 25, 2023, grants of non-qualified stock
options to purchase 258,300 shares of its common stock (the
“September 25th Options”) and restricted stock units (“RSUs”)
covering 43,050 shares of its common stock under the Inducement
Plan to a new employee. Also, effective September 29, 2023, the
Compensation Committee approved grants of non-qualified stock
options to purchase an aggregate of 297,355 shares of its common
stock (the “September 29th Options”) and RSUs covering an aggregate
of 55,268 shares of its common stock under the Inducement Plan to
six new employees.
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
ImmunoGen (or following a bona fide period of non-employment), as
an inducement material to such individual’s entering into
employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
The September 25th Options and the September 29th Options have
exercise prices of $14.63 and $15.87 per share, which is equal to
the closing price of ImmunoGen’s common stock on the Nasdaq Global
Select Market on September 25, 2023 and September 29, 2023,
respectively. Each option granted under the September 25th Options
and the September 29th Options will vest as to 25% of the shares
underlying such option on the first anniversary of the grant date
and as to an additional 6.25% of the shares underlying the option
quarterly thereafter, subject to each employee’s continued
employment on each vesting date. Each RSU under all grants will
vest as to 25% of the shares underlying the RSU award on the first
anniversary of the grant date and as to an additional 25% of the
shares underlying the RSU award annually thereafter, subject to
each employee’s continued employment on each vesting date. Each
option under the September 25th Options and the September 29th
Options and each RSU under all grants is subject to the terms and
conditions of the Inducement Plan and the terms and conditions of a
stock option agreement and an RSU agreement covering the respective
grants.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates to improve outcomes for cancer patients. By generating
targeted therapies with enhanced anti-tumor activity and favorable
tolerability profiles, we aim to disrupt the progression of cancer
and offer our patients more good days. We call this our commitment
to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230928192083/en/
INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com
MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024